1. Home
  2. ARDX vs TRVI Comparison

ARDX vs TRVI Comparison

Compare ARDX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$7.99

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$10.93

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
TRVI
Founded
2007
2011
Country
United States
United States
Employees
N/A
34
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
ARDX
TRVI
Price
$7.99
$10.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
12
Target Price
$12.95
$20.38
AVG Volume (30 Days)
6.3M
1.2M
Earning Date
02-19-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$398,234,000.00
N/A
Revenue This Year
$22.65
N/A
Revenue Next Year
$31.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
58.12
N/A
52 Week Low
$3.21
$3.47
52 Week High
$8.17
$14.39

Technical Indicators

Market Signals
Indicator
ARDX
TRVI
Relative Strength Index (RSI) 66.23 41.31
Support Level $6.73 $10.17
Resistance Level $7.25 $11.78
Average True Range (ATR) 0.57 0.72
MACD 0.14 -0.12
Stochastic Oscillator 89.03 29.84

Price Performance

Historical Comparison
ARDX
TRVI

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: